WTW Outperforms Industry, Trades at a Discount: How to Play the Stock

Willis Towers Watson (WTW) shares have outperformed its industry and the S&P 500 over the past year, gaining 18.7% and consistently surpassing earnings estimates, while trading at a forward P/E of 17.17x, a discount to the industry average. Despite strategic acquisitions and strong segment performance driving revenue growth and analyst projections of an 18.9% upside, the insurer faces challenges from rising expenses that are compressing margins and a trailing ROE of 20.5% that lags the industry average, leading to recent downward revisions in future earnings estimates by some analysts.

Analysis

Willis Towers Watson (WTW) presents a mixed but compelling profile for investors. The company's shares have demonstrated strong performance, gaining 18.7% over the past year and outperforming both its industry and the S&P 500 composite. This is supported by a consistent history of surpassing earnings estimates, with an average beat of 15.99% over the last four quarters. From a valuation perspective, WTW appears attractive, trading at a forward 12-month P/E of 17.17x, a significant discount to the industry average of 21.58x, while analyst targets suggest a potential 18.9% upside. Growth is underpinned by strategic acquisitions that have expanded its global footprint and a focus on core opportunities in its Risk & Broking and Individual Marketplace segments, which have contributed to 15 consecutive quarters of revenue growth in most regions. Furthermore, the company maintains a solid balance sheet and is committed to capital returns, evidenced by a planned $1.5 billion share repurchase in 2025. However, several headwinds warrant caution. Rising expenses, including costs from a transformation program, are actively compressing margins. Critically, the company's trailing 12-month ROE of 20.5% lags the industry average of 27.3%, indicating lower efficiency in utilizing shareholder funds. This concern is echoed by recent analyst sentiment, with several lowering earnings estimates for 2025 and 2026, causing a slight decline in consensus forecasts.

Key Decisions for Investors

• Investors may consider the current valuation an attractive entry point, given the stock's 17.17x forward P/E trades at a discount to the industry and analysts project a potential 18.9% upside.
• It is critical to monitor the company's expense management and progress on its Transformation program, as rising costs are the primary factor compressing profit margins.
• The combination of recent downward earnings estimate revisions and a subpar ROE of 20.5% warrants a cautious stance, suggesting investors should weigh the growth narrative against clear profitability and efficiency challenges.
• Potential investors should track the performance of the core Risk & Broking and Health, Wealth & Career segments, as their continued growth is essential to offsetting margin pressures and meeting forward-looking revenue projections.